These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33766649)

  • 21. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biology of HDAC in cancer: the nuclear and epigenetic components.
    Hagelkruys A; Sawicka A; Rennmayr M; Seiser C
    Handb Exp Pharmacol; 2011; 206():13-37. PubMed ID: 21879444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
    Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
    Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An insight into therapeutic efficacy of heterocycles as histone-modifying enzyme inhibitors that targets cancer epigenetic pathways.
    Basha NJ; Basavarajaiah SM
    Chem Biol Drug Des; 2022 Nov; 100(5):682-698. PubMed ID: 36059065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review.
    Saito Y; Saito H; Liang G; Friedman JM
    Clin Rev Allergy Immunol; 2014 Oct; 47(2):128-35. PubMed ID: 24362548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
    Hosokawa M; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approaches to target the genome and its epigenome in cancer.
    Chapman-Rothe N; Brown R
    Future Med Chem; 2009 Nov; 1(8):1481-95. PubMed ID: 21426061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view.
    Hodjat M; Rahmani S; Khan F; Niaz K; Navaei-Nigjeh M; Mohammadi Nejad S; Abdollahi M
    Arch Toxicol; 2017 Jul; 91(7):2577-2597. PubMed ID: 28516248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review-Epigenetic therapy for cancer.
    Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
    Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic tools in potential anticancer therapy.
    Sebova K; Fridrichova I
    Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments.
    Schnekenburger M; Florean C; Dicato M; Diederich M
    Curr Top Med Chem; 2016; 16(7):745-76. PubMed ID: 26303418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
    Ramakrishnan S; Pili R
    Cancer J; 2013; 19(4):333-40. PubMed ID: 23867515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
    Oh S; Ko JY; Oh C; Yoo KH
    Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
    Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
    Hadnagy A; Beaulieu R; Balicki D
    Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.